President Donald Trump has announced a major set of tariffs targeting imported goods. From October 1, branded and patented medicines entering the United States will face a 100 percent duty unless companies run factories on American soil.
The plan also includes a 25 percent tariff on heavy-duty trucks and a 50 percent levy on kitchen and bathroom cabinets. Trump unveiled the measures on Thursday, calling them essential to protect US manufacturers.
On Truth Social, he said a “flood” of imports was harming American producers. He argued the tariffs would support domestic companies and protect US jobs.
The announcement comes despite repeated warnings from US businesses that new duties could disrupt supply chains and raise costs.
Pharmaceutical industry reacts
Neil Shearing, chief economist at Capital Economics, said the pharmaceutical tariffs were less sweeping than they appeared. He noted exemptions for generic drugs and companies investing in US factories.
He added that many major pharmaceutical companies already operate US facilities or plan to expand production.
Ireland’s Trade Minister Simon Harris cited the August 21 US-EU deal, which capped tariffs on European pharmaceutical exports at 15 percent.
United Nations data show Britain exported more than six billion dollars’ worth of medicines to the US last year.
A June trade deal between Washington and London also pledged “preferential treatment outcomes on pharmaceuticals.”
A UK government spokesperson described the announcement as concerning and said Britain would continue close engagement with US officials.
UK drugmakers boost US investment
GlaxoSmithKline already operates American plants. Last week, it pledged 30 billion dollars in US research and manufacturing over five years.
AstraZeneca also runs US facilities. In July, it announced plans to invest 50 billion dollars in the country by 2030.
William Bain, head of trade policy at the British Chambers of Commerce, said these investments should shield UK companies from new tariffs. He highlighted advanced manufacturing projects already underway.
Several pharmaceutical firms have recently withdrawn planned investments from Britain, citing challenging conditions.
Jane Sydenham, investment director at Rathbones, said Trump’s policies were a key factor. She argued US trade uncertainty outweighed concerns about Britain’s slower growth.
Tariffs extend to trucks and furniture
Trump confirmed a 25 percent duty on heavy-duty trucks. He said the measure would benefit US manufacturers such as Peterbilt and Mack Trucks.
He also announced duties on kitchen and bathroom cabinets and other furniture imports. He said high import volumes were harming domestic producers.
From next week, upholstered furniture will face a 30 percent tariff.
Swedish retailer Ikea said the tariffs complicate operations and added it is closely monitoring developments.
Tariffs remain central to Trump’s trade agenda
Tariffs continue to define Trump’s second-term economic strategy. In August, sweeping duties on imports from over 90 countries came into effect. Washington said the measures aim to strengthen US manufacturing and create jobs.
Earlier tariffs had targeted steel, copper, aluminium, cars and vehicle parts.
The US Chamber of Commerce warned against new duties this year. It noted that most truck parts come from Mexico, Canada, Germany, Finland and Japan.
Mexico and Canada supplied more than half of US imports of medium and heavy truck parts last year. The chamber said domestic production was unrealistic and would push costs higher.
Experts warn of higher prices
Deborah Elms, trade analyst at the Hinrich Foundation, said the tariffs benefit US producers but are “terrible” for consumers. She predicted rising prices across multiple sectors.
She explained that the new measures cover more products and set higher rates than Trump’s earlier reciprocal tariffs, which aimed to correct trade imbalances.
Elms added that industry-specific duties could serve as a fallback plan. They could provide revenue if broader global tariffs are challenged in court.
